Lenalidomide Auxilia (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s activity, leading to the targeted degradation of transcription factors Ikaros and Aiolos. The resulting anti‑angiogenic, immunomodulatory, and anti‑proliferative actions help suppress malignant cell growth.

The dose of Lenalidomide Auxilia is individualized. A qualified prescriber determines the appropriate strength, schedule, and duration based on the specific indication, disease stage, patient weight, renal function, and other clinical factors. Patients should follow the prescribing information provided by their healthcare professional.

Lenalidomide is classified as potentially harmful to a developing fetus, and its safety in pregnancy has not been established. Women of childbearing potential should use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended while taking lenalidomide because the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lenalidomide Auxilia. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Lenalidomide is a second‑generation immunomodulatory imide drug that generally offers greater potency and a more favorable safety profile than thalidomide. It has stronger anti‑angiogenic and immunomodulatory effects while typically causing fewer peripheral neuropathy events. However, both drugs share risks such as thrombosis and myelosuppression, so selection depends on the specific disease, prior therapy, and patient tolerance.

Lenalidomide Auxilia should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat. Do not store in the bathroom or near a kitchen sink. Ensure the container is tightly closed when not in use to maintain product stability.

Lenalidomide Auxilia is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets (or capsules) should be swallowed whole with a full glass of water. Patients must follow the exact dosing schedule provided, and any missed dose should be addressed according to the prescriber’s instructions.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to life‑threatening infections or bleeding; thromboembolic events such as deep‑vein thrombosis or pulmonary embolism; and the potential development of secondary primary malignancies. Patients should report signs of infection, unusual bruising, shortness of breath, or new pain promptly to their healthcare provider.

Lenalidomide Auxilia is contraindicated in individuals with known hypersensitivity to lenalidomide or any component of the formulation. It should also be avoided in pregnant women and in patients who cannot use effective contraception. Patients with uncontrolled infections, severe renal impairment without appropriate monitoring, or those on incompatible medications should discuss alternatives with their clinician.